Show simple item record

dc.contributor.authorIndalo, Anne A
dc.contributor.authorKokwaro, GO
dc.date.accessioned2013-05-31T12:00:04Z
dc.date.available2013-05-31T12:00:04Z
dc.date.issued1995-08
dc.identifier.citationEast Afr Med J. 1995 Aug;72(8):483-5en
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/7588138
dc.identifier.urihttp://profiles.uonbi.ac.ke/aindalo/publications/pharmacokinetics-temazepam-male-surgical-patientseast-afr-med-j-1995-aug728483-
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/28338
dc.description.abstractThe pharmacokinetics of temazepam, the 3-hydroxy1 derivative of diazepam, were studied in nine male surgical patients (age: 28-57 years; weight: 55-87 kg) who had ingested single 40 mg doses, 4 hours prior to minor surgical procedures. Peak plasma temazepam concentrations were achieved rapidly (within 1 h post drug administration) and the estimated volume of distribution (mean: 1.13 1/kg), total clearance (mean: 1.6 ml/min/kg) and terminal elimination half-life (mean: 8 hours) were comparable to previously reported values in healthy subjects. There was no correlation between volume of distribution and either weight or age, and between clearance and age. These findings are broadly consistent with previous reports from studies in healthy subjects. Temazepam can therefore be used as a premedicant in patients requiring minor surgery; the concomitant anaesthetic agents administered and the surgical procedures have no effects on temazepam pharmacokineticsen
dc.language.isoenen
dc.publisherUniversity of Nairobi.en
dc.titlePharmacokinetics of temazepam in male surgical patientsen
dc.typeArticleen
local.publisherDepartment of Clinical Pharmacology and Therapeutics, Faculty of Pharmacyen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record